

**First Supplement dated October 9, 2026
to the Base Prospectus dated August 14, 2026**

This document constitutes a supplement (the **First Supplement**) for the purposes of Art. 8(10) and 23(1) of Regulation (EU) 2017/1129 of the European Parliament and the Council of June 14, 2017, as amended (the **Prospectus Regulation**) to the base prospectus (the **Prospectus**) of Fresenius Medical Care AG as issuer (the **Issuer**) in respect of non-equity securities within the meaning of Article 2(c) of the Prospectus Regulation (the **Non-Equity Securities**).



Fresenius Medical Care AG
(Hof (Saale), Federal Republic of Germany)

EUR 10,000,000,000
Debt Issuance Programme
(the **Programme**)

The *Commission de Surveillance du Secteur Financier* (the **CSSF**) of the Grand Duchy of Luxembourg in its capacity as competent authority under the Prospectus Regulation has approved this First Supplement as a supplement within the meaning of Art. 23(1) of the Prospectus Regulation. By approving this First Supplement, CSSF gives no undertaking as to the economic and financial soundness of the operation or the quality or solvency of the Issuer.

The Issuer has requested the CSSF to provide the competent authority in the Federal Republic of Germany (**Germany**) with a certificate of approval attesting that this First Supplement has been drawn up in accordance with the Prospectus Regulation. The Issuer may request the CSSF to provide competent authorities in additional host member states within the European Economic Area with such notification.

This First Supplement together with the Prospectus and the documents incorporated by reference herein and therein are available for viewing on the website of the Luxembourg Stock Exchange (www.luxse.com).

In accordance with Art. 23(2) of the Prospectus Regulation, where the Prospectus relates to an offer of Notes to the public, investors who had already agreed to purchase or subscribe for the securities before the First Supplement was published and where such securities had not yet been delivered to the investors at the time when the significant new factor, material mistake or material inaccuracy arose or was noted, have the right, exercisable within three working days after the publication of this First Supplement, to withdraw their acceptances. The final date of the right of withdrawal will be October 14, 2026. Investors should contact Fresenius Medical Care AG, Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H., Federal Republic of Germany for the exercise of the right of withdrawal.

The purpose of this First Supplement is to update the disclosure contained in the Prospectus.

This First Supplement is supplemental to and should be read in conjunction with the Base Prospectus dated August 14, 2026. Terms defined in the Prospectus have the same meaning when used in this First Supplement.

The Issuer is solely responsible for the information given in this First Supplement. The Issuer hereby declares that, having taken all reasonable care to ensure that such is the case, the information contained in this First Supplement for which it is responsible, is, to the best of its knowledge, in accordance with the facts and omits no information likely to affect its import.

To the extent that there is any inconsistency between any statement included in this First Supplement and any statement included or incorporated by reference in the Prospectus, the statements in this First Supplement will prevail.

Except as disclosed in this First Supplement, there has been no other significant new factor, material mistake or material inaccuracy relating to information included in the Prospectus which could affect the assessment of Notes to be issued under the Programme since the publication of the Prospectus.

No person has been authorized to give any information which is not contained in or not consistent with the Prospectus or the First Supplement or any other document entered into in relation to the Programme or any information supplied by the Issuer or any other information in the public domain and, if given or made, such information must not be relied upon as having been authorized by the Issuer, the Dealers or any of them.

No person has been authorized to give any information or to make any representation other than those contained in the Prospectus or this First Supplement in connection with the issue or sale of the Notes and, if given or made, such information or representation must not be relied upon as having been authorized by the Issuer, the Dealers or any of them.

This First Supplement does not constitute an offer of, or an invitation by or on behalf of the Issuer or the Dealers to subscribe for, or purchase, any Notes.

The Issuer announces the following changes with regard to the Prospectus:

I. REPLACEMENT AND SUPPLEMENTAL INFORMATION PERTAINING TO THE SECTION "BUSINESS OF THE GROUP"

1. Recent Events

The section "Recent Events" on page 80 of the Prospectus shall be supplemented by including the following paragraph:

"On October 7, 2026, the Company announced the appointment of Shervin J. Korangy as a member of the Management Board, effective October 12, 2026. The Supervisory Board unanimously appointed him to succeed Helen Giza, who has served as CEO and Chair of the Management Board for four years, following three years as CFO. Shervin Korangy is a seasoned global executive with extensive leadership experience and deep domain know-how in healthcare and life sciences. He has led multinational businesses and brings a strong track record in global expansion, portfolio innovation and strategic transformation across complex international organizations. Most recently, as CEO of U.S.-headquartered BVI Medical, he transformed the business into a global leader in surgical eye care. Having served on FME's Supervisory Board since 2023, he also has a deep understanding of the dialysis business, its strategic context and its key opportunities. He will work with the management team to build on the Company's strong foundation and shape its next phase of growth."

NAMES AND ADDRESSES

THE ISSUER

Fresenius Medical Care AG
Else-Kröner-Straße 1
61352 Bad Homburg v. d. H.
Germany